The stem cell hard sell: Report from a clinic’s patient recruitment seminar

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The growing direct-to-consumer, stem cell clinic industry in the U.S. uses a number of strategies for patient recruitment, including self-styled educational seminars, which may reach thousands of members of the public annually. Here I report on a first-hand experience at such a seminar that I recently attended. Numerous specific medical claims were made at the seminar: no potential for rejection; no side effects, including no pain; proven efficacy for a variety of conditions, including in particular arthritis and pain; and U.S. Food and Drug Administration approval. I discuss the potential impact of these kinds of seminars on the public and on the stem cell field.

Original languageEnglish (US)
Pages (from-to)14-16
Number of pages3
JournalStem cells translational medicine
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Patient Selection
Stem Cells
Drug Approval
Pain
Arthritis
Industry
Food
Rejection (Psychology)

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

The stem cell hard sell : Report from a clinic’s patient recruitment seminar. / Knoepfler, Paul S.

In: Stem cells translational medicine, Vol. 6, No. 1, 01.01.2017, p. 14-16.

Research output: Contribution to journalArticle

@article{ad5981b88d1044de969c4c81f1c0ae75,
title = "The stem cell hard sell: Report from a clinic’s patient recruitment seminar",
abstract = "The growing direct-to-consumer, stem cell clinic industry in the U.S. uses a number of strategies for patient recruitment, including self-styled educational seminars, which may reach thousands of members of the public annually. Here I report on a first-hand experience at such a seminar that I recently attended. Numerous specific medical claims were made at the seminar: no potential for rejection; no side effects, including no pain; proven efficacy for a variety of conditions, including in particular arthritis and pain; and U.S. Food and Drug Administration approval. I discuss the potential impact of these kinds of seminars on the public and on the stem cell field.",
author = "Knoepfler, {Paul S}",
year = "2017",
month = "1",
day = "1",
doi = "10.5966/sctm.2016-0208",
language = "English (US)",
volume = "6",
pages = "14--16",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "1",

}

TY - JOUR

T1 - The stem cell hard sell

T2 - Report from a clinic’s patient recruitment seminar

AU - Knoepfler, Paul S

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The growing direct-to-consumer, stem cell clinic industry in the U.S. uses a number of strategies for patient recruitment, including self-styled educational seminars, which may reach thousands of members of the public annually. Here I report on a first-hand experience at such a seminar that I recently attended. Numerous specific medical claims were made at the seminar: no potential for rejection; no side effects, including no pain; proven efficacy for a variety of conditions, including in particular arthritis and pain; and U.S. Food and Drug Administration approval. I discuss the potential impact of these kinds of seminars on the public and on the stem cell field.

AB - The growing direct-to-consumer, stem cell clinic industry in the U.S. uses a number of strategies for patient recruitment, including self-styled educational seminars, which may reach thousands of members of the public annually. Here I report on a first-hand experience at such a seminar that I recently attended. Numerous specific medical claims were made at the seminar: no potential for rejection; no side effects, including no pain; proven efficacy for a variety of conditions, including in particular arthritis and pain; and U.S. Food and Drug Administration approval. I discuss the potential impact of these kinds of seminars on the public and on the stem cell field.

UR - http://www.scopus.com/inward/record.url?scp=85017405858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017405858&partnerID=8YFLogxK

U2 - 10.5966/sctm.2016-0208

DO - 10.5966/sctm.2016-0208

M3 - Article

C2 - 28170181

AN - SCOPUS:85017405858

VL - 6

SP - 14

EP - 16

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 1

ER -